Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Gains US OK For Fasenra In Patient-Friendly Form

Levels playing field with GSK's Nucala

Executive Summary

The company is keeping up the pressure on GSK, getting approval for self-administration for Fasenra a few months after a similar green light for severe asthma rival Nucala.

You may also be interested in...



Novartis Culls Fevipiprant After LackLUSTER Data

Any lingering hopes Novartis had that fevipiprant could become a blockbuster have disappeared and the Swiss major has ended development of the asthma drug after two more trials failed, this time for severe disease.

GSK's Trelegy On Track To Be First Triple Inhaled Regimen For Asthma

The company filed an sNDA with the US FDA for the triple combination, hoping to expand its current COPD indication to also include asthma.

AZ Explores Orphan Diseases To Boost Fasenra Growth

The company's severe asthma drug Fasenra has demonstrated its effectiveness in a Phase II trial for hypereosinophilic syndrome, a group of rare disorders which can cause progressive organ damage.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel